drugset / Trial / NCT00130039

Trial of Cilostazol in Symptomatic Intracranial Arterial Stenosis II

NCT00130039 ↗

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will recruit 480 acute stroke patients with symptomatic intracranial stenosis (M1 segment of Middle cerebral artery (MCA) or basilar artery). They will be randomly assigned into cilostazol group or clopidogrel group. Every patients will take 100mg of aspirin a day additionally. The primary outcome variable of this study is Progression rate of symptomatic intracranial stenosis on magnetic resonance angiogram (MRA).

Timeline

Start
2005-08
Primary completion
2009-01
Completion
2009-01

Outcome

Missed primary endpoint

paper Cilostazol did not reduce the progression of symptomatic ICAS (20 of 202) compared to clopidogrel (32 of 207) (odds ratio, 0.61; P=0.092) PMID 21799173 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Cilostazol Small molecule 100 mg —
Comparator Clopidogrel Small molecule 75 mg —